133 related articles for article (PubMed ID: 34060427)
1. Cytochrome P450 2C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients:
Joshi K; Kaur S; Kumar R
J Biomol Struct Dyn; 2022; 40(19):9389-9402. PubMed ID: 34060427
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of the CYP2C19*2 (681 G>A), *3 (636 G>A) and *17 (‑806 C>T) alleles among an Iranian population of different ethnicities.
Dehbozorgi M; Kamalidehghan B; Hosseini I; Dehghanfard Z; Sangtarash MH; Firoozi M; Ahmadipour F; Meng GY; Houshmand M
Mol Med Rep; 2018 Mar; 17(3):4195-4202. PubMed ID: 29328413
[TBL] [Abstract][Full Text] [Related]
3. The Molecular and Enzyme Kinetic Basis for Altered Activity of Three Cytochrome P450 2C19 Variants Found in the Chinese Population.
Dong AN; Ahemad N; Pan Y; Palanisamy UD; Yiap BC; Ong CE
Curr Mol Pharmacol; 2020; 13(3):233-244. PubMed ID: 31713493
[TBL] [Abstract][Full Text] [Related]
4. Estimation of polymorphisms in the drug-metabolizing enzyme, cytochrome
Ahmed S; Gul S; Akhlaq M; Hussain A; Tariq Khan S; Rehman H; Hanif Bangash M; Al Mughairbi F; Hamid Hamdard M
Bioengineered; 2021 Dec; 12(1):4442-4451. PubMed ID: 34308762
[TBL] [Abstract][Full Text] [Related]
5. [The polymorphism of cytochrome P(450) 2C19 gene in patients with invasive fungal infections.].
Wu JQ; Zhu LP; Ou XT; Xu B; Zhang QQ; Weng XH
Zhonghua Nei Ke Za Zhi; 2010 Feb; 49(2):138-41. PubMed ID: 20356512
[TBL] [Abstract][Full Text] [Related]
6. Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population.
Tayeb HT; Bakheet DH; Zaza K; Wakil SM; Dzimiri N
J Pharm Pharmacol; 2015 Jul; 67(7):972-9. PubMed ID: 25684066
[TBL] [Abstract][Full Text] [Related]
7. Individuals having variant genotypes of cytochrome P450 2C19 are at increased risk of developing primary liver cancer in Han populations, without infection with the hepatitis virus.
Li QY; Zhao NM; Wang LC; Duan HF; Ma YC; Zhang W; Zhao HW; Qin YH
Tumour Biol; 2014 Sep; 35(9):9023-6. PubMed ID: 24906606
[TBL] [Abstract][Full Text] [Related]
8. Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.
Annuar AA; Ankathil R; Mohd Yunus N; Husin A; Ab Rajab NS; Abdul Aziz AA; Ibrahim MI; Sulong S
Asian Pac J Cancer Prev; 2021 Feb; 22(2):565-571. PubMed ID: 33639675
[TBL] [Abstract][Full Text] [Related]
9. CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia.
Taspinar M; Aydos SE; Comez O; Elhan AH; Karabulut HG; Sunguroglu A
Swiss Med Wkly; 2008 Jan; 138(1-2):12-7. PubMed ID: 18224491
[TBL] [Abstract][Full Text] [Related]
10. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
11. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Zhong Z; Hou J; Zhang Q; Li B; Li C; Liu Z; Yang M; Zhong W; He X; Wu H; Zhong M; Zhao P
Eur J Clin Pharmacol; 2018 Apr; 74(4):423-431. PubMed ID: 29243114
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphism, linkage disequilibrium, haplotype structure and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese.
Zhou Q; Yu XM; Lin HB; Wang L; Yun QZ; Hu SN; Wang DM
Pharmacogenomics J; 2009 Dec; 9(6):380-94. PubMed ID: 19636337
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP1A1, GST polymorphisms and susceptibility risk of chronic myeloid leukemia in Syrian population.
Al-Achkar W; Azeiz G; Moassass F; Wafa A
Med Oncol; 2014 May; 31(5):889. PubMed ID: 24671854
[TBL] [Abstract][Full Text] [Related]
14. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
15. The -137G/C Polymorphism in Interleukin-18 Gene Promoter Contributes to Chronic Lymphocytic and Chronic Myelogenous Leukemia Risk in Turkish Patients.
Yalçın S; Mutlu P; Çetin T; Sarper M; Özgür G; Avcu F
Turk J Haematol; 2015 Dec; 32(4):311-6. PubMed ID: 26376814
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Iranian population.
Zand N; Tajik N; Moghaddam AS; Milanian I
Clin Exp Pharmacol Physiol; 2007; 34(1-2):102-5. PubMed ID: 17201743
[TBL] [Abstract][Full Text] [Related]
17. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
18. Association between genetic polymorphisms of cytochrome P450 2C19 and the risk of cerebral ischemic stroke in Chinese.
Gu S; Sun Y; Han R; Wang L; Wang D; Wang J; Li X
BMC Med Genet; 2014 Jul; 15():83. PubMed ID: 25030528
[TBL] [Abstract][Full Text] [Related]
19. Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China.
Zhong Z; Hou J; Li B; Zhang Q; Liu S; Li C; Liu Z; Yang M; Zhong W; Zhao P
Med Sci Monit; 2017 Dec; 23():6186-6192. PubMed ID: 29288619
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
